197 related articles for article (PubMed ID: 22337714)
1. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.
Lepretre S; Aurran T; Mahé B; Cazin B; Tournilhac O; Maisonneuve H; Casasnovas O; Delmer A; Leblond V; Royer B; Corront B; Chevret S; Delépine R; Vaudaux S; Van Den Neste E; Béné MC; Letestu R; Cymbalista F; Feugier P
Blood; 2012 May; 119(22):5104-10. PubMed ID: 22337714
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
Davids MS; Brander DM; Kim HT; Tyekucheva S; Bsat J; Savell A; Hellman JM; Bazemore J; Francoeur K; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng S; Crombie J; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Fisher DC; Brown JR;
Lancet Haematol; 2019 Aug; 6(8):e419-e428. PubMed ID: 31208944
[TBL] [Abstract][Full Text] [Related]
3. Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Herishanu Y; Tadmor T; Braester A; Bairey O; Aviv A; Rahimi-Levene N; Fineman R; Levi I; Yuklea M; Ruchlemer R; Shvidel L; Polliack A
Hematol Oncol; 2019 Apr; 37(2):185-192. PubMed ID: 30756414
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
5. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.
Awan FT; Hillmen P; Hellmann A; Robak T; Hughes SG; Trone D; Shannon M; Flinn IW; Byrd JC;
Br J Haematol; 2014 Nov; 167(4):466-77. PubMed ID: 25130401
[TBL] [Abstract][Full Text] [Related]
6. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A
Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474
[TBL] [Abstract][Full Text] [Related]
7. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
Reynolds C; Di Bella N; Lyons RM; Hyman W; Richards DA; Robbins GJ; Vellek M; Boehm KA; Zhan F; Asmar L
Invest New Drugs; 2012 Jun; 30(3):1232-40. PubMed ID: 21922186
[TBL] [Abstract][Full Text] [Related]
8. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Byrd JC; Kipps TJ; Flinn IW; Castro J; Lin TS; Wierda W; Heerema N; Woodworth J; Hughes S; Tangri S; Harris S; Wynne D; Molina A; Leigh B; O'Brien S
Blood; 2010 Jan; 115(3):489-95. PubMed ID: 19843887
[TBL] [Abstract][Full Text] [Related]
9. Chemoimmunotherapy with oral low-dose fludarabine, cyclophosphamide and rituximab (old-FCR) as treatment for elderly patients with chronic lymphocytic leukaemia.
Gozzetti A; Candi V; Fabbri A; Schiattone L; Cencini E; Lauria F; Frasconi A; Crupi R; Raspadori D; Papini G; Defina M; Bartalucci G; Bocchia M
Leuk Res; 2014 Aug; 38(8):891-5. PubMed ID: 24934847
[TBL] [Abstract][Full Text] [Related]
10. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
11. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
Smolej L; Brychtová Y; Cmunt E; Doubek M; Špaček M; Belada D; Šimkovič M; Stejskal L; Zygulová I; Urbanová R; Brejcha M; Zuchnická J; Móciková H; Kozák T;
Br J Haematol; 2021 May; 193(4):769-778. PubMed ID: 33618437
[TBL] [Abstract][Full Text] [Related]
12. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia.
Parikh SA; Keating MJ; O'Brien S; Wang X; Ferrajoli A; Faderl S; Burger J; Koller C; Estrov Z; Badoux X; Lerner S; Wierda WG
Blood; 2011 Aug; 118(8):2062-8. PubMed ID: 21750315
[TBL] [Abstract][Full Text] [Related]
13. Rituximab, fludarabine, and cyclophosphamide versus fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia: A systematic review with meta-analysis.
Nunes AA; da Silva AS; Souza KM; Koury Cde N; de Mello LM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):261-9. PubMed ID: 25797826
[TBL] [Abstract][Full Text] [Related]
14. The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab.
Panovská A; Smolej L; Lysák D; Brychtová Y; Šimkovič M; Motyčková M; Vodárek P; Lindtnerová M; Trbušek M; Malčíková J; Pospíšilová Š; Mayer J; Doubek M
Eur J Haematol; 2013 Jun; 90(6):479-85. PubMed ID: 23506191
[TBL] [Abstract][Full Text] [Related]
15. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Hallek M; Fischer K; Fingerle-Rowson G; Fink AM; Busch R; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Bergmann M; Catalano J; Zinzani PL; Caligaris-Cappio F; Seymour JF; Berrebi A; Jäger U; Cazin B; Trneny M; Westermann A; Wendtner CM; Eichhorst BF; Staib P; Bühler A; Winkler D; Zenz T; Böttcher S; Ritgen M; Mendila M; Kneba M; Döhner H; Stilgenbauer S; ;
Lancet; 2010 Oct; 376(9747):1164-74. PubMed ID: 20888994
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
Badoux XC; Keating MJ; Wang X; O'Brien SM; Ferrajoli A; Faderl S; Burger J; Koller C; Lerner S; Kantarjian H; Wierda WG
Blood; 2011 Aug; 118(8):2085-93. PubMed ID: 21670470
[TBL] [Abstract][Full Text] [Related]
18. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia.
Strati P; Wierda W; Burger J; Ferrajoli A; Tam C; Lerner S; Keating MJ; O'Brien S
Cancer; 2013 Nov; 119(21):3805-11. PubMed ID: 23943357
[TBL] [Abstract][Full Text] [Related]
19. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
